BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 12859261)

  • 1. Timolol 0.5%/dorzolamide 2% fixed combination versus timolol 0.5%/pilocarpine 2% fixed combination in primary open-angle glaucoma or ocular hypertensive patients.
    Kałuzny JJ; Szaflik J; Czechowicz-Janicka K; Kałuzny J; Orzalkiewicz A; Zaleska A; Krajewska M; Stewart JA; Leech JN; Stewart WC
    Acta Ophthalmol Scand; 2003 Aug; 81(4):349-54. PubMed ID: 12859261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Timolol 0.5%/dorzolamide 2% fixed combination versus timolol 0.5%/pilocarpine 2% fixed combination in primary open-angle glaucoma or ocular hypertensive patients].
    Kałuzny JJ; Szaflik J; Czechowicz-Janicka K; Kałuzny J; Orzałkiewicz A; Zaleska-Zmijewska A; Krajewska M; Stewart JA; Leech JN; Stewart WC
    Klin Oczna; 2004; 106(1-2 Suppl):241-2. PubMed ID: 15510513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Twenty-four-hour diurnal curve comparison of commercially available latanoprost 0.005% versus the timolol and dorzolamide fixed combination.
    Konstas AG; Papapanos P; Tersis I; Houliara D; Stewart WC
    Ophthalmology; 2003 Jul; 110(7):1357-60. PubMed ID: 12867391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and tolerability of the dorzolamide 2%/timolol 0.5% combination (COSOPT) versus 0.005% (XALATAN) in the treatment of ocular hypertension or glaucoma: results from two randomized clinical trials.
    Fechtner RD; Airaksinen PJ; Getson AJ; Lines CR; Adamsons IA;
    Acta Ophthalmol Scand; 2004 Feb; 82(1):42-8. PubMed ID: 14982045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension.
    Sezgin Akçay Bİ; Güney E; Bozkurt KT; Unlü C; Akçali G
    J Ocul Pharmacol Ther; 2013 Dec; 29(10):882-6. PubMed ID: 24180628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Timolol 0.5%/dorzolamide 2% fixed combination vs timolol maleate 0.5% and unoprostone 0.15% given twice daily to patients with primary open-angle glaucoma or ocular hypertension.
    Day DG; Schacknow PN; Wand M; Sharpe ED; Stewart JA; Leech J; Stewart WC
    Am J Ophthalmol; 2003 Feb; 135(2):138-43. PubMed ID: 12566015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of fixed-combination bimatoprost/timolol versus fixed-combination dorzolamide/brimonidine/timolol in patients with primary open-angle glaucoma or ocular hypertension: a multicenter, prospective, crossover study.
    García-López A; Paczka JA; Jiménez-Román J; Hartleben C
    BMC Ophthalmol; 2014 Dec; 14():161. PubMed ID: 25527295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of bimatoprost 0.03% versus timolol maleate 0.5%/dorzolamide 2% fixed combination.
    Day DG; Sharpe ED; Beischel CJ; Jenkins JN; Stewart JA; Stewart WC
    Eur J Ophthalmol; 2005; 15(3):336-42. PubMed ID: 15945001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of latanoprost with fixed-combination dorzolamide and timolol in adult patients with elevated intraocular pressure: an eight-week, randomized, open-label, parallel-group, multicenter study in Latin America.
    Susanna R; Sheu WP;
    Clin Ther; 2004 May; 26(5):755-68. PubMed ID: 15220019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of the fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressure.
    Shin DH; Feldman RM; Sheu WP;
    Ophthalmology; 2004 Feb; 111(2):276-82. PubMed ID: 15019375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide. Dorzolamide-Timolol Study Group.
    Boyle JE; Ghosh K; Gieser DK; Adamsons IA
    Ophthalmology; 1998 Oct; 105(10):1945-51. PubMed ID: 9787368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide.
    Boyle JE; Ghosh K; Gieser DK; Adamsons IA
    Ophthalmology; 1999 Dec; 106(12 Suppl):10-6. PubMed ID: 10598692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 24-Hour Efficacy and Ocular Surface Health with Preservative-Free Tafluprost Alone and in Conjunction with Preservative-Free Dorzolamide/Timolol Fixed Combination in Open-Angle Glaucoma Patients Insufficiently Controlled with Preserved Latanoprost Monotherapy.
    Konstas AG; Boboridis KG; Kapis P; Marinopoulos K; Voudouragkaki IC; Panayiotou D; Mikropoulos DG; Pagkalidou E; Haidich AB; Katsanos A; Quaranta L
    Adv Ther; 2017 Jan; 34(1):221-235. PubMed ID: 27913991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the efficacy and tolerability of preservative-free and preservative-containing formulations of the dorzolamide/timolol fixed combination (COSOPT™) in patients with elevated intraocular pressure in a randomized clinical trial.
    Shedden A; Adamsons IA; Getson AJ; Laurence JK; Lines CR; Hewitt DJ; Ho TW
    Graefes Arch Clin Exp Ophthalmol; 2010 Dec; 248(12):1757-64. PubMed ID: 20437244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of dorzolamide and pilocarpine as adjunctive therapy to timolol in patients with elevated intraocular pressure. The Dorzolamide Additivity Study Group.
    Strahlman ER; Vogel R; Tipping R; Clineschmidt CM
    Ophthalmology; 1996 Aug; 103(8):1283-93. PubMed ID: 8764800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An eight-week, multicentric, randomized, interventional, open-label, phase 4, parallel comparison of the efficacy and tolerability of the fixed combination of timolol maleate 0.5%/brimonidine tartrate 0.2% versus fixed combination of timolol maleate 0.5%/dorzolamide 2% in patients with elevated intraocular pressure.
    Hatanaka M; Grigera DE; Barbosa WL; Jordao M; Susanna R
    J Glaucoma; 2008 Dec; 17(8):674-9. PubMed ID: 19092465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circadian intraocular pressure control with dorzolamide versus timolol maleate add-on treatments in primary open-angle glaucoma patients using latanoprost.
    Tamer C; Oksüz H
    Ophthalmic Res; 2007; 39(1):24-31. PubMed ID: 17164574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Daytime diurnal curve comparison between the fixed combinations of latanoprost 0.005%/timolol maleate 0.5% and dorzolamide 2%/timolol maleate 0.5%.
    Konstas AG; Kozobolis VP; Lallos N; Christodoulakis E; Stewart JA; Stewart WC
    Eye (Lond); 2004 Dec; 18(12):1264-9. PubMed ID: 15218522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of ocular hypotensive actions of fixed combinations of brimonidine/timolol and dorzolamide/timolol.
    García-Feijoó J; Sáenz-Francés F; Martínez-de-la-Casa JM; Méndez-Hernández C; Fernández-Vidal A; Calvo-González C; García-Sánchez J
    Curr Med Res Opin; 2010 Jul; 26(7):1599-606. PubMed ID: 20429818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of latanoprost versus pilocarpine/timolol maleate fixed combination in patients with primary open-angle glaucoma or ocular hypertension.
    Kałuzny J; Sobecki R; Czechowicz-Janicka K; Kecik D; Kałuzny BJ; Stewart JA; Stewart WC
    Acta Ophthalmol; 2008 Dec; 86(8):860-5. PubMed ID: 18721251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.